Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10938684 | 0.98 | LMNA (0.53) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL10780206 | 0.98 | LMNA (0.53) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL5883487 | 0.98 | LMNA (0.51) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL5883668 | 0.95 | ALDH1A1 (0.51) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL493858 | 0.88 | TSHR (0.43) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL14323854 | 0.79 | PAOX (0.38) | ALDH1A1KMT2APRKCAABCB1 | |
| Cyclohexane SCHEMBL1289332 | 0.78 | TSHR (0.74) | LMNAALDH1A1TSHRKMT2AEPHX2 | |
| SCHEMBL10777080 | 0.77 | MAPT (0.47) | LMNATSHRKMT2ARECQL | |
| SCHEMBL10456238 | 0.77 | MAPT (0.47) | LMNATSHRKMT2ARECQL | |
| SCHEMBL10940844 | 0.77 | MAPT (0.47) | LMNATSHRKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | LMNA 3674/4885ALDH1A1 923/4885TSHR 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.